Literature DB >> 8486943

VDRL antibodies enhance phagocytosis of Treponema pallidum by macrophages.

S A Baker-Zander1, J M Shaffer, S A Lukehart.   

Abstract

Although reactivity in nontreponemal tests develops in patients with untreated syphilis, no immunologic function has been ascribed to these antibodies. This study demonstrates that rabbit antibodies induced by immunization with VDRL antigen and VDRL antibodies affinity-purified from syphilitic rabbit serum enhance phagocytosis of Treponema pallidum. The proportion of macrophages ingesting treponemes in the presence of these antisera was 45% +/- 5% and 27% +/- 4%, respectively, versus 14% +/- 3% for normal serum (P < .001 and P < .01). Both IgG and IgM fractions contained opsonic activity. Absorption of VDRL antibodies from syphilitic serum diminished but did not eliminate opsonization, suggesting at least two classes of target molecules. Despite opsonic capacity, VDRL antibodies fail to facilitate macrophage-mediated killing of T. pallidum. Nevertheless, VDRL-immunized rabbits are partially protected against T. pallidum infection, developing fewer lesions (delayed and smaller) than do unimmunized controls. These results suggest a heretofore unrecognized functional role for VDRL antibodies in syphilis infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8486943     DOI: 10.1093/infdis/167.5.1100

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Membrane topology and cellular location of the Treponema pallidum glycerophosphodiester phosphodiesterase (GlpQ) ortholog.

Authors:  D V Shevchenko; T J Sellati; D L Cox; O V Shevchenko; E J Robinson; J D Radolf
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Syphilis: using modern approaches to understand an old disease.

Authors:  Emily L Ho; Sheila A Lukehart
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

3.  Quantitative assessment of protection in experimental syphilis.

Authors:  Cheryl I Champion; David R Blanco; Michael A Lovett
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 4.  Biological basis for syphilis.

Authors:  Rebecca E Lafond; Sheila A Lukehart
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

5.  Surface immunolabeling and consensus computational framework to identify candidate rare outer membrane proteins of Treponema pallidum.

Authors:  David L Cox; Amit Luthra; Star Dunham-Ems; Daniel C Desrosiers; Juan C Salazar; Melissa J Caimano; Justin D Radolf
Journal:  Infect Immun       Date:  2010-09-27       Impact factor: 3.441

6.  Reduced Treponema pallidum-Specific Opsonic Antibody Activity in HIV-Infected Patients With Syphilis.

Authors:  Christina M Marra; Lauren C Tantalo; Sharon K Sahi; Shelia B Dunaway; Sheila A Lukehart
Journal:  J Infect Dis       Date:  2015-12-09       Impact factor: 5.226

7.  A monoclonal antibody that conveys in vitro killing and partial protection in experimental syphilis binds a phosphorylcholine surface epitope of Treponema pallidum.

Authors:  David R Blanco; Cheryl I Champion; Alek Dooley; David L Cox; Julian P Whitelegge; Kym Faull; Michael A Lovett
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

8.  Treponema pallidum elicits innate and adaptive cellular immune responses in skin and blood during secondary syphilis: a flow-cytometric analysis.

Authors:  Juan C Salazar; Adriana R Cruz; Constance D Pope; Liliana Valderrama; Rodolfo Trujillo; Nancy G Saravia; Justin D Radolf
Journal:  J Infect Dis       Date:  2007-02-05       Impact factor: 5.226

9.  Characterization of outer membranes isolated from Treponema pallidum, the syphilis spirochete.

Authors:  J D Radolf; E J Robinson; K W Bourell; D R Akins; S F Porcella; L M Weigel; J D Jones; M V Norgard
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 10.  Vaccines for bacterial sexually transmitted infections: a realistic goal?

Authors:  P F Sparling; C Elkins; P B Wyrick; M S Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.